SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging on heavy volume as investors speculate on potential institutional accumulation and positive developments ahead of the upcoming earnings call. The community is buzzing over the stock reclaiming key psychological levels, with longs betting on long-term growth driven by the company's TIL therapy pipeline while shorts face intensifying pressure.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending due to significant community debate over its volatile price action, with many investors pointing to aggressive short selling and manipulation as the primary catalysts for the recent downturn despite record-breaking business growth. While bears highlight rising competition and macro-headwinds, the bullish community remains focused on strong international expansion, high demand for brands like Alani Nu, and a highly anticipated earnings catalyst they believe will trigger a massive short squeeze.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors debate the potential for a third BLA resubmission following management's claim of an aligned path forward with the FDA, despite significant skepticism regarding the company's financial runway, headcount reductions, and previous regulatory rejections. Community discussion remains heavily polarized between bulls anticipating a binary regulatory turnaround and bears highlighting the firm's lack of revenue, dilution risks, and the challenging hurdle of securing approval after multiple CRLs.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to community debate surrounding reports that the company is considering charging high-dollar monthly fees to provide institutional investors with expedited access to Truth Social posts. Investors and community members are sharply divided over the firm's monetization strategies, while ongoing political discourse regarding election integrity continues to drive intense engagement across the platform.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is facing intense community volatility as investors debate the impact of a recent treasury exploit against the potential for a market-wide meme coin rally. The discourse is polarized, with some users calling for immediate exits due to security concerns while others aggressively buy the dip in anticipation of a broader bull cycle.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is seeing heightened investor attention driven by ongoing operational advancements in its phase 3 FLAMINGO-01 trial and growing anticipation ahead of ASCO participation. The community is actively debating the potential for partnership or buyout outcomes, while monitoring trial enrollment metrics and the strategic implications of upcoming regulatory updates.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation associated with Alzheimer's disease dementia, a milestone that significantly expands the drug's market potential. The community is focused on the drug's clean safety label, its role as a first-in-class non-antipsychotic option, and the impact of the upcoming product launch alongside the company's robust CNS pipeline.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as it battles Nvidia for the title of the world's most valuable company, with investors rotating into its stock as a perceived defensive safe haven amid broader tech volatility. While the community remains divided over its high valuation and limited AI innovation, strong institutional buying and positive analyst upgrades are driving sentiment, prompting heated debates between bullish traders following the breakout and bearish voices calling the move a manipulated market-stabilization tactic.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing heightened volatility and intense social media scrutiny as investors brace for the critical July 29 FDA advisory committee meeting concerning Deramiocel. While the community remains deeply divided between long-term supporters focused on robust clinical trial results and vocal critics questioning manufacturing disputes and potential data-blinding procedures, bullish sentiment persists as institutional ownership increases ahead of the PDUFA date.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant bearish pressure and heavy short interest, with the community actively debating whether the recent 50% pullback is an accumulation opportunity or a sign of deeper fundamental issues. Investors are closely monitoring key support levels near $30-$33 while calling for concrete project handover news to catalyze a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up   - Here's Why

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...

Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering

(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...

239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc

Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

MAZEMaze Therapeutics Inc.

Fundamentals

Latest MAZE News